Impact of Clay Siegall in Cancer Treatment

Clay Siegall is the co-founder, President, the Chief Executive Officer, and the Chairman of the Board of Directors of Seattle Genetics. Clay Siegall founded the company in 1998 after working in different medical institutions such as the National Cancer Institute, National Institutes, Bristol-Myers Squibb Pharmaceutical Research Institute, and BioPharmaceuticals. Dr. Siegall has a Ph.D. in Genetics and a B.S in Zoology from George Washington University and the University of Maryland respectively.

Seattle Genetics has seen massive developments under the leadership of Dr. Clay Siegall. Through his leadership, the firm was able to secure an FDA approval of its ADC product, ADCETRIS in 2011. He has also guided the company in developing antibody-drug conjugates (ADCs). He has also helped make ADCETRIS a global drug through collaboration with Takeda Pharmaceutical Company. Dr. Siegall has made Seattle Genetics grow into a diverse production of ADCs for the treatment of cancer.

Dr. Siegall has aided in the fight against cancer by the production of cancer vaccines and sitting in multiple cancer boards. He has helped Seattle Genetics enter multiple strategic licenses that have seeded more than $350 million.

Dr. Siegall is an author of more than 70 publications, articles and holds 15 patents. Some of his articles are discussed below.

Why are people not using a vaccine that can significantly change the lives of many people living with cancer? Human papillomavirus (HPV) vaccine is a vaccine which was discovered over a decade ago and can prevent more than 90% of all cervical cancers, other cancers, and sexually transmitted infections. However, the vaccine has not gained popularity as it is supposed to have. To get the virus to most people around the world, the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices have reduced the HPV dose from three to two for kids between 9 and 14 years.

Researchers have discovered a new machine called BrainGate2. The device allows paralyzed people to decode their thoughts and control their muscles and organs such as arms. The device operates by determining the movement which an individual wants to perform; then it electrically stimulates the muscles in the arm to perform the movement.